


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification⁶: C07D 237/04, 405/04, A61K 31/50	A1	(11) International publication number: WO 99/65880 (43) International publication date: 23 December 1999 (23.12.99)
(21) International application number: PCT/EP99/03151 (22) International filing date: 7 May 1999 (07.05.99) (30) Data relating to the priority: 198 26 841.6 16 June 1998 (16.06.98) DE (71) Applicant (for all designated States except US): MERCK PATENT GMBH [DE/DE]; Frankfurter Strasse 250, D-64293 Darmstadt (DE). (72) Inventors; and (75) Inventors/Applicants (US only): JONAS, Rochus [DE/DE]; Stormstrasse 7, D-64291 Darmstadt (DE). WOLF, Michael [DE/DE]; Nußbaumalle 59, D-64297 Darmstadt (DE). KLUXEN, Franz-Werner [DE/DE]; Bessunger Strasse 3, D-64285 Darmstadt (DE). 01.02.00 (74) Joint Representative: MERCK PATENT GMBH; Postfach, D-64271 Darmstadt (DE).		(81) Designated states: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, <u>SG</u> , SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO Patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With the International Search Report.

As printed

(54) Title: ARYL ALKANOYLPYRIDAZINES

(54) Bezeichnung: ARYLALKANOYLPYRIDAZINE



(57) Abstract

The invention relates to aryl alkanoylpyridazine derivatives of the formula (I) and their physiologically compatible salts and solvates, where R¹, R², Q and B have the meanings given in claim 1. Said compounds have a phosphodiesterase-IV inhibiting action and can be used in the treatment of allergic disorders, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, auto-immune diseases such as rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disturbances, atherosclerosis and AIDS.

(57) Zusammenfassung

Arylalkanoylpyridazinderivate der Formel (I), sowie deren physiologisch unbedenkliche Salze und Solvate, worin R¹, R², Q und B die in Anspruch 1 angegebenen Bedeutungen haben, zeigen eine Phosphodiesterase IV-Hemmung und können zur Behandlung von allergischen Krankheiten, Asthma, chronischer Bronchitis, atopischer Dermatitis, Psoriasis und anderer Hautkrankheiten, entzündlichen Krankheiten, Autoimmunerkrankungen, wie z.B. rheumatoide Arthritis, multiple Sklerose, Morbus Crohn, Diabetes mellitus oder ulcerative Kolitis, Osteoporose, Transplantatabstoßungsreaktionen, Kachexie, Tumorstadium oder Tumormetastasen, Sepsis, Gedächtnisstörungen, Atherosklerose und AIDS eingesetzt werden.